Special Issue "Tumor Associated Macrophages"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 September 2013)
Prof. Dr. Reto Schwendener
Institute of Molecular Cancer Research, Laboratory of Liposome Research, University of Zurich, CH-8057 Zurich, Switzerland
Website | E-Mail
Interests: tumor microenvironment; stromal cells; macrophages; tumor associated macrophages; neutrophils; tumor associated neutrophils; myeloid derived suppressor cells; immune cells; fibroblasts; stromal interactions; bisphosphonates; clodronate; macrophage depletion; liposomes; nanocarriers; nanomedicine; therapeutic targets; repolarization; reprogramming; immunotherapy; adjuvant cancer therapy; therapies aiming at the tumor microenvironment
This issue invites experts to contribute original research reports as well as review articles that describe studies on tumor associated macrophages (TAM) and other immune cells that infiltrate the tumor microenvironment (TME) and that either promote or inhibit growth, invasion and spread of tumors. Solid tumors grow within a complex microenvironment composed of diverse cell types such as fibroblasts, endothelial cells, mast cells, macrophages and other immune cells that are attracted by tumor cell derived factors and embedded in an extracellular matrix. Molecular and cellular interactions between epithelial cells and cells surrounding the tumor stroma promote growth, invasion and spread of tumors. To delay or impede tumor growth, the TME is increasingly being explored as a potential therapeutic target for which novel strategies are developed.
Contributions describing biological function and properties of the TME and drugs or treatments that aim at the repolarization of a pro-tumorigenic, immunosuppressive environment to a tumor growth inhibiting and immunocompetent microenvironment are welcome.
Potential topics include, but are not limited to:
• Biology of the TME with emphasis on TAM or other immune cells that infiltrate the TME
• Description of new findings related to interactions of tumor cells with the TME
• Therapy concepts aiming at the TME to inhibit tumor growth
• Development of novel drug carrier systems for TME targeting
Prof. Dr. Reto Schwendener
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tumor microenvironment
- tumor associated macrophages
- immune cells
- stromal interactions
- repolarization, reprogramming
- immunotherapy, adjuvant cancer therapy
- macrophage depletion
- drug targeting